JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 24, 2007; DOI: 10.1124/jpet.106.117861


0022-3565/07/3211-276-287$20.00
JPET 321:276-287, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.117861v1
321/1/276    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, H.-l.
Right arrow Articles by Hollenberg, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, H.-l.
Right arrow Articles by Hollenberg, P. F.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

The Inactivation of Cytochrome P450 3A5 by 17{alpha}-Ethynylestradiol Is Cytochrome b5-Dependent: Metabolic Activation of the Ethynyl Moiety Leads to the Formation of Glutathione Conjugates, a Heme Adduct, and Covalent Binding to the Apoprotein

Hsia-lien Lin, and Paul F. Hollenberg

Department of Pharmacology, University of Michigan, Ann Arbor, Michigan

17{alpha}-Ethynylestradiol (EE) inactivates cytochrome P450 3A5 (3A5) in the reconstituted system in a mechanism-based manner. The inactivation is dependent on NADPH, and it is irreversible. The inactivation of 3A5 by EE is also dependent on cytochrome b5 (b5). The values for the KI and kinact of the 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation activity of 3A5 are 26 µM and 0.06 min–1, respectively. Incubation of 3A5 with EE resulted in a 62% loss of catalytic activity, 60% loss in the reduced CO difference spectrum, and 40% decrease in native heme with the formation of a heme adduct. The partition ratio was ~25, and the stoichiometry of binding was ~0.3 mol of EE metabolite bound/mol of P450 inactivated. Four major metabolites were formed during the metabolism of EE by 3A5. SDS-polyacrylamide gel electrophoresis analysis demonstrated that [3H]EE was irreversibly bound to 3A5 apoprotein. Liquid chromatography-tandem mass spectrometry analysis (LC-MS/MS) revealed that two glutathione (GSH) conjugates with m/z values of 620 were formed only in the presence of b5. These two conjugates are formed from the reaction of GSH with the ethynyl group with the oxygen being inserted into either the internal or terminal carbon. A heme adduct with the ion at m/z 927 and two dipyrrole adducts with ions at m/z 579 were detected by LC-MS/MS analysis. In conclusion, 3A5 can activate EE to a 17{alpha}-oxirene-related reactive species that can then partition the oxygen between the internal and terminal carbons of the ethynyl group to form heme and apoprotein adducts, resulting in the inactivation of P450 3A5.


Received November 30, 2006; accepted January 22, 2007.

Address correspondence to: Dr. Paul F. Hollenberg, Department of Pharmacology, 2301 MSRB III, 1150 West Medical Center Dr., Ann Arbor, MI 48109-0632. E-mail: phollen{at}umich.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
H.-l. Lin, H. Zhang, and P. F. Hollenberg
Metabolic Activation of Mifepristone [RU486; 17{beta}-Hydroxy-11{beta}-(4-dimethylaminophenyl)-17{alpha}-(1-propynyl)-estra-4,9-dien-3-one] by Mammalian Cytochromes P450 and the Mechanism-Based Inactivation of Human CYP2B6
J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 26 - 37.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. S. Kartha and G. S. Yost
Mechanism-Based Inactivation of Lung-Selective Cytochrome P450 CYP2F Enzymes
Drug Metab. Dispos., January 1, 2008; 36(1): 155 - 162.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.